99120-49-7

Basic information

• Product Name: GLP-2 (HUMAN)
• Synonyms: HADGSFSDEMNTILDNLAARDFINWLIQTKITDR;H-HIS-ALA-ASP-GLY-SER-PHE-SER-ASP-GLU-MET-ASN-THR-ILE-LEU-ASP-ASN-LEU-ALA-ALA-ARG-ASP-PHE-ILE-ASN-TRP-LEU-ILE-GLN-THR-LYS-ILE-THR-ASP-ARG-OH;H-HIS-ALA-ASP-GLY-SER-PHE-SER-ASP-GLU-MET-ASN-THR-ILE-LEU-ASP-ASN-LEU-ALA-ALA-ARG-ASP-PHE-ILE-ASN-TRP-LEU-ILE-GLN-THR-LYS-ILE-THR-ASP-OH;HIS-ALA-ASP-GLY-SER-PHE-SER-ASP-GLU-MET-ASN-THR-ILE-LEU-ASP-ASN-LEU-ALA-ALA-ARG-ASP-PHE-ILE-ASN-TRP-LEU-ILE-GLN-THR-LYS-ILE-THR-ASP;GLUCAGON-LIKE PEPTIDE-2;GLUCAGON-LIKE PEPTIDE 2 ARG (HUMAN);GLUCAGON-LIKE PEPTIDE 2 (HUMAN);GLUCAGON-LIKE PEPTIDE II HUMAN
• CAS NO: 99120-49-7
• Molecular Formula: C171H266N48O56S1
• Molecular Weight: 3922.29
• Product Categories: Peptide
• Mol File: 99120-49-7.mol
• Article Data: 0

Chemical Properties

• Appearance: /solid
• Storage Temp.: −20°C
• CAS DataBase Reference: GLP-2 (HUMAN)(CAS DataBase Reference)
• NIST Chemistry Reference: GLP-2 (HUMAN)(99120-49-7)
• EPA Substance Registry System: GLP-2 (HUMAN)(99120-49-7)

Safety Data

• Safety Statements: 22-24/25
• WGK Germany: 3
• Hazardous Substances Data: 99120-49-7(Hazardous Substances Data)

Usage

Uses

Glucagon-Like Peptide 2 (GLP-2) -Arg human trifluoroacetate salt has been used for injection in chickens to determine the effects of GLP-2 on the weight and morphology of small intestines.

General Description

Glucagon-like peptide 2 (GLP-2) is a member of the pro-glucagon gene family which is released in small and large intestinal circulation by enteroendocrine L cells. This peptide is composed of 33 amino acids.

Biochem/physiol Actions

Glucagon-like peptide 2 (GLP-2) influences the functionality of gastrointestinal tract by participating in the feedback loop to the brain for the control of food intake. It also controls digestion and absorption, and has tropic effects post chemotherapy injury or surgical resection. This peptide is also responsible for epithelial cell proliferation of the small bowel. Studies in rats show that this peptide enhances the effects of the ileal-brake hormones, GLP-1 and peptide YY. It also negatively regulates gastrointestinal motility and secretion. Thus, it has potential as a therapeutic agent in short-bowel syndrome.